Results 31 to 40 of about 74,852 (258)
Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer
Frontiers in Oncology, 2020 Purpose: PARP inhibitors are a novel targeted anti-cancer drug and a large number of clinical studies on PARP inhibitors have been accomplished. This updated meta-analysis was conducted to evaluate the efficacy and safety of PARP inhibitors in advanced ...
Yifan Jiang +9 more
doaj +1 more source
PARP inhibitors as anticancer agents
, 2021 The PARP enzyme family is a heterogeneous group of enzymes that are involved in a myriad of intracellular processes from maintaining genomic integrity, modulating inflammatory responses, and regulating cellular metabolism, to name a few.
Oladapo, Emmanuel Taiwo
core
PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them
, 2022 PARP inhibitors are the first clinically approved drugs that were developed based on synthetic lethality. PARP inhibitors have shown promising outcomes since their clinical applications and have recently been approved as maintenance treatment for cancer ...
Dongha Kim +3 more
core +1 more source
Frontiers in Pharmacology, 2021 Background: Poly(ADP-ribose) polymerase (PARP) inhibitors have breakthrough designations for metastatic castration-resistant prostate cancer (mCRPC). We performed a meta-analysis of current clinical trials to evaluate the efficacy of PARP inhibitors in ...
Kan Wu +5 more
doaj +1 more source
PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting
, 2017 Poly(ADP-ribose) polymerases have shown true promise in early clinical studies due to reported activity in BRCA-associated cancers. PARP inhibitors may represent a potentially important new class of chemotherapeutic agents directed at targeting cancers ...
Karolina N. Dziadkowiec +3 more
core +1 more source
PARP Inhibitors and Proteins Interacting with SLX4
, 2023 PARP inhibitors are small molecules currently used with success in the treatment of certain cancer patients. Their action was first shown to be specific to cells with DNA repair deficiencies, such as BRCA-mutant cancers.
Lars Petter Jordheim +1 more
core +1 more source
Pharmacology and clinical use of Poly (ADP- ribose) polymerase inhibitors in breast cancer
, 2023 Breast cancer is very diverse illness. Treatment of breast cancer that contain genetic mutations and DNA repair deficiencies with PARP inhibitors is showing a promising result. BRCA 1 and BRCA 2 patients respond very well to this treatment. Also, studies
Kaddoura, Haitham
core
Hyperosmotic stress induces PARP1‐mediated HPF1‐dependent mono(ADP‐ribosyl)ation
FEBS Letters, EarlyView.Sorbitol‐induced hyperosmotic stress rapidly induces reversible mono(ADP‐ribosyl)ation (MARylation) on PARP1 without the signs of genotoxic signaling. We show that PARP1 autoMARylation is HPF1 dependent and forms hydroxylamine‐resistant O‐glycosidic linkages.
Anna Georgina Kopasz +11 more
wiley +1 more source
Molecular Oncology, EarlyView.Dimethyl fumarate (DMF) reduces growth of HPV‐positive cervical cancer spheroids and induces ferroptosis in cervical cancer cells via blocking SLC7A11/Glutathione (GSH) axis. Combination of subcytotoxic doses of DMF and cisplatin (CDDP) further suppresses spheroid growth and drives cell death in 2D culture models.
Carolina Punziano +6 more
wiley +1 more source
Proteogenomic characterization of cholangiocarcinoma
Hepatology, EarlyView., 2022 Proteogenomic characterization of cholangiocarcinoma with therapeutic strategies Abstract Background and Aims Cholangiocarcinoma (CCA) is a highly heterogeneous cancer with limited understanding and few effective therapeutic approaches. We aimed at providing a proteogenomic CCA characterization to inform biological processes and treatment ...
Mengjie Deng +18 more
wiley +1 more source